Top Markets
Coin of the day
Arvee Laboratories (India) Ltd. Arvee Laboratories (India) Ltd.

Arvee Laboratories (India) Ltd.

ARVEE
Classificação em ações #29422
Arvee Laboratories (India) Ltd., established in 2012 and headquartered in... Arvee Laboratories (India) Ltd., established in 2012 and headquartered in Ahmedabad, India, specializes in the production and distribution of various specialized chemicals throughout the country. The company's product line includes a range of polymer modifiers, such as dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate. Additionally, Arvee Laboratories manufactures intermediates critical for contrast media, supplying compounds like 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, dimethyl 5-aminoisophthalate, 3,5-dinitrobenzoic acid, and 3,5-diamino benzoic acid. The firm also provides drug intermediates, specifically 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4-amino pyridine, and 2-chloro-5-nitrobenzoic acid. Beyond its domestic sales, Arvee Laboratories actively exports its chemical products.
Preço da ação
$1.92
Valor de mercado
$21.21M
Variação (1 dia)
2.25%
Variação (1 ano)
4.23%
País
IN
Negociar Arvee Laboratories (India) Ltd. (ARVEE)
Lucros da Arvee Laboratories (India) Ltd. (ARVEE)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Arvee Laboratories (India) Ltd., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Arvee Laboratories (India) Ltd. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$9.38B -
GB
- -
FR
$3.49B -
US
$2.63B -
US
$-82.10M -
US